Objectives: To assess the budgetary impact from the reimbursement of bimekizumab in Greece for patients with moderate-to-severe hidradenitis suppurativa (HS).

Methods: A budget impact model was locally adapted from the National Organization for Health Services (EOPYY) perspective to assess the economic impact of reimbursing bimekizumab for HS in Greece over five-years (2026-2030). Two scenarios were compared: with and without bimekizumab in HS market. Epidemiological data were retrieved from published literature and validated by local clinical experts. Market shares for bimekizumab and its comparators—adalimumab and secukinumab—were provided by UCB estimates. Clinical inputs were based on phase III trials (BE HEARD I and II) and a network meta-analysis to inform efficacy and safety measures, using Hidradenitis Suppurativa Clinical Response (HiSCR) to assess treatment responses. The analysis included direct costs relevant to the EOPYY perspective, such as drug acquisition, monitoring, administration, disease management, and adverse events. Unit costs (€,2024) were derived from official databases and literature, while resource use provided by local clinical experts. Treatments followed EMA-approved dosing, aligned with national clinical practice.

Results: The eligible HS population for treatment with biologic disease-modifying antirheumatic drugs (DMARDs) ranged from 571 patients (first year) to 937 patients (fifth year). Within this population, bimekizumab was assumed to capture 5% market share in the first year, increasing to 23% by the fifth year. The budget impact analysis (BIA) estimates that the introduction and gradual uptake of bimekizumab would lead to an incremental cost to the EOPYY budget of approximately €342,336 in the first year and €2,707,559 in the fifth year.

Conclusions: The BIA concludes that the introduction of bimekizumab for HS treatment in Greece would result in an average annual budget impact of €1,570,400 over five-years. While this represents a measurable increase in healthcare spending, it is considered acceptable given the high unmet need and therapeutic benefit.